Alvotech (ALVO) Stock Price, Quote & News

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indicatio...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: www.alvotech.com

Address:

9, Rue de Bitbourg, Luxembourg, Luxembourg

SuperGreenToday May. 11 at 5:19 PM

$ALVO

0 · Reply

JohnTill May. 11 at 3:34 PM

$ALVO Clean break of the 50MA and huge wedge. Market holding her should be a very clean technical breakout and time to fill that gap to 8.00. Second time is the charm and there was a reason I liked this pattern and seen similar ones work out so many times over the decades. Time for the FDA filing and new drug announcement just to get things really rolling.

0 · Reply

JohnTill May. 11 at 2:15 PM

$ALVO The market often has a knee-jerk reaction to convertible debt but think they have this one wrong. The convertible bond to me looked like a strategic move to bring fresh institutional money into the story at the right time. ALVO has an unusually strong insider backstop. Aztiq Pharma Partners, Celtic Holdings S.C.A., and ATP Holdings ehf together own roughly 65% of the company, with all roads leading back to founder Róbert Wessman. These groups have deep pockets and already showed support by buying 10 million shares in December to backstop the offering. ALVO did not need outside money just to keep the lights on. The bond brings new institutional investors into the stock and gives new professional investors a direct reason to help the market understand the ALVO story. The initial conversion price is $5.9224, a 25% premium to the reference price. ALVO can force conversion at double digits in the net two years, which I expect them to do. That looks bullish to me.

1 · Reply

JohnTill May. 11 at 11:15 AM

$ALVO Great news and another big derisking event. Give 50% of foreign firms receive a minor Form 483 and 15% receive a severe notice a minor notice was the expected and almost best outcome. Given past violations a completely clean inspection would have been surprising. We should now be golden for late 2026 US launch, which as means upside of 180-220 million EBITDA and 650-700 million revenue range for 2026. Given Q1, those are some big numbers coming. Market is supposedly always right but in my opinion downside from here is rather minimal given all the previous factors discussed and upside is double digits next year. Buying more on this news.

1 · Reply

Toffik72 May. 11 at 10:14 AM

$ALVO Alvotech announces completion of FDA surveillance inspection at Reykjavik facility; https://investors.alvotech.com/news-releases/news-release-details/alvotech-announces-completion-fda-surveillance-inspection Key points from the announcement: 1) FDA completed the surveillance inspection That means the inspection is over. 2)FDA did issue a Form 483, so observations existed. But Alvotech explicitly says: observations are addressable quickly, there are no “substantial issues” with the facility or operations. 3)They still expect BLA resubmissions in Q2 2026 This is probably the most market-important sentence. If FDA had found major systemic manufacturing problems, Alvotech likely would not say: “well positioned to resubmit” and “expect approval during 2026.” So looks like management strongly believes that the observations are limited and manageable, and don tblock resubmissions. I find this line particularly important: “demonstrates the strong cGMP fundamentals of the site” Lets see if any reaction on SP today

0 · Reply

Toffik72 May. 11 at 9:45 AM

$ALVO Alvotech announces completion of FDA surveillance inspection at Reykjavik facility; investors.alvotech.com/news... Key points from the announcement: 1) FDA completed the surveillance inspection That means the inspection is over. 2)FDA did issue a Form 483, so observations existed. But Alvotech explicitly says: observations are addressable quickly, there are no “substantial issues” with the facility or operations. 3)They still expect BLA resubmissions in Q2 2026 This is probably the most market-important sentence. If FDA had found major systemic manufacturing problems, Alvotech likely would not say: “well positioned to resubmit” and “expect approval during 2026.” So looks like management strongly believes that the observations are limited and manageable, and don tblock resubmissions. I find this line particularly important: “demonstrates the strong cGMP fundamentals of the site” Lets see if any reaction on SP today

0 · Reply

Luc7777 May. 8 at 8:02 AM

$ALVO don't you guys think they went into typical scam with convertible notes

1 · Reply

diggs24 May. 7 at 9:49 PM

$ALVO Added 1000@$3.20

0 · Reply

Luc7777 May. 7 at 7:19 PM

$ALVO Any thoughts on what was said during EC and Q&A?

1 · Reply

ppl_first May. 7 at 2:38 PM

$ALVO failure to execute. Major incompetence.

1 · Reply

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

May 6, 2026, 4:30 PM EDT - 6 days ago

Alvotech Q1 2026 Financial Results

Apr 30, 2026, 4:30 PM EDT - 12 days ago

Alvotech Announces a Change in its Executive Team

Apr 24, 2026, 8:30 AM EDT - 19 days ago

Alvotech to Report Financial Results for the First Quarter of 2026

Mar 30, 2026, 7:58 PM EDT - 6 weeks ago

Alvotech files Annual Report with the SEC

Mar 30, 2026, 7:55 PM EDT - 6 weeks ago

Alvotech Publishes 2025 Annual Report

Mar 18, 2026, 6:15 PM EDT - 7 weeks ago

Alvotech Q4 2025 and Full Year 2025 Financial Results

Mar 4, 2026, 3:00 AM EST - 2 months ago

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 11, 2026, 11:00 AM EST - 3 months ago

Alvotech Announces Increase in Number of Own Shares

Feb 5, 2026, 3:00 AM EST - 3 months ago

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Feb 2, 2026, 3:00 AM EST - 3 months ago

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Jan 7, 2026, 5:00 PM EST - 4 months ago

Correction: Transactions of Managers and Closely Associated Persons

Jan 6, 2026, 3:00 PM EST - 4 months ago

Transactions of Managers and Closely Associated Persons

Dec 31, 2025, 4:30 PM EST - 4 months ago

Alvotech Secures Term Loan Facility of USD 100 Million

Dec 29, 2025, 2:40 PM EST - 4 months ago

Changes in company's own shares

Dec 22, 2025, 3:26 PM EST - 5 months ago

Alvotech's Financial Calendar for 2026

Dec 22, 2025, 2:00 AM EST - 5 months ago

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Dec 17, 2025, 2:30 AM EST - 5 months ago

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

Nov 24, 2025, 5:30 AM EST - 6 months ago

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Nov 20, 2025, 4:00 AM EST - 6 months ago

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Nov 12, 2025, 4:40 PM EST - 6 months ago

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Nov 10, 2025, 5:28 PM EST - 6 months ago

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 6, 2025, 6:28 PM EST - 6 months ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 6, 2025, 9:07 AM EST - 6 months ago

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Nov 4, 2025, 4:01 PM EST - 6 months ago

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Nov 2, 2025, 5:12 PM EST - 6 months ago

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Oct 22, 2025, 5:00 AM EDT - 7 months ago

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Oct 6, 2025, 4:40 AM EDT - 7 months ago

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Sep 22, 2025, 6:15 AM EDT - 8 months ago

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

Sep 22, 2025, 4:30 AM EDT - 8 months ago

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Sep 19, 2025, 7:45 AM EDT - 8 months ago

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Sep 4, 2025, 9:15 AM EDT - 8 months ago

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Aug 21, 2025, 4:30 AM EDT - 9 months ago

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Aug 20, 2025, 6:05 AM EDT - 9 months ago

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Aug 13, 2025, 4:15 PM EDT - 9 months ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 13, 2025, 4:15 PM EDT - 9 months ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 6, 2025, 8:00 AM EDT - 10 months ago

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Jul 10, 2025, 4:40 AM EDT - 10 months ago

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Jul 9, 2025, 4:30 AM EDT - 11 months ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

Jul 9, 2025, 4:30 AM EDT - 11 months ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Jul 3, 2025, 7:02 PM EDT - 11 months ago

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Jul 1, 2025, 7:54 PM EDT - 11 months ago

Granting of Stock Options and Vesting of Restricted Share Units

SuperGreenToday May. 11 at 5:19 PM

$ALVO

0 · Reply

JohnTill May. 11 at 3:34 PM

0 · Reply

JohnTill May. 11 at 2:15 PM

1 · Reply

JohnTill May. 11 at 11:15 AM

1 · Reply

Toffik72 May. 11 at 10:14 AM

0 · Reply

Toffik72 May. 11 at 9:45 AM

0 · Reply

Luc7777 May. 8 at 8:02 AM

$ALVO don't you guys think they went into typical scam with convertible notes

1 · Reply

diggs24 May. 7 at 9:49 PM

$ALVO Added 1000@$3.20

0 · Reply

Luc7777 May. 7 at 7:19 PM

$ALVO Any thoughts on what was said during EC and Q&A?

1 · Reply

ppl_first May. 7 at 2:38 PM

$ALVO failure to execute. Major incompetence.

1 · Reply

Kosmokrat May. 7 at 2:11 PM

My take on Q1 numbers and today’s earnings call: Overall: $ALVO’s business model is working, they are growing revenues double digit, with an expected acceleration in 2027. Profitability is around the corner, they will be cash flow positive this year. They re-confirmed guidance for 2026. Overall, 2026 will be a year of relatively slow growth for $ALVO, with 2027 with a significant acceleration of growth in revenue and profits. In Q1 there was an impact in manufacturing due to the changes that are being implemented as response to the concerns of the FDA. These changes should be finalized in Q2, so manufacturing will commence with full throughput very soon. $ALVO sees this as a short term investment into the future. Currently there is an FDA inspection going on, which should be concluded later this week. Resubmission of the BLAs for AVT03, AVT05 and AVT06 are still targeted for Q2, the US launch for these product are still targeted for Q4 2026, or early 2027 the latest.

1 · Reply

i_jw May. 7 at 11:13 AM

$ALVO Seems like Q2 will be pivotal? If they deliver there then the story is derisked and proven and stock should easily gap up 100% from here.

0 · Reply

i_jw May. 7 at 10:53 AM

$ALVO Im wondering what is the competition like in this space? There is Gedeon Richter. But will this be a chokepoint in a massive market or will there be 12 competitors 5 years from now? If it is a chokepoint with massive demand this will be the NVDA of biotech.

2 · Reply

StocktwitsEarnings May. 7 at 10:00 AM

$ALVO Q1 '26 Earnings Results & Recap Management anticipates Alvotech's total revenues to be in the range of $650M and adjusted EBITDA in the range of $180M in 2026, with the lower revenue end assuming no new U.S. market launches.

0 · Reply

diggs24 May. 6 at 10:08 PM

$ALVO Buying more tomorrow.

0 · Reply

JohnTill May. 6 at 9:45 PM

$ALVO I'm really hoping the broader market wakes up and realizes that this U.S. agreement with FUJIFILM is a massive, long-term de-risking event. I certainly see it that way. FUJIFILM is an absolute heavyweight in the U.S. biomanufacturing space, and are well-known for their ability to replicate and quicky ramp up these complex manufacturing processes. Given their recent multi-billion-dollar expansion down in Holly Springs, it is highly likely ALVO has been quietly eyeing that capacity for a while. With FUJIFILM's digital tech transfer capabilities at the helm, we could realistically see U.S. production up and running in just over a year. That timeline lines up perfectly for ALVO's 2027-2028 U.S.launches. Honestly, the negative after-hours price action is baffling if you are looking at the long game. However, it is likely the market just throwing a short-sighted tantrum over the Q1 top-line revenue miss completely ignoring all the positives.

1 · Reply

JohnTill May. 6 at 9:23 PM

$ALVO Color me stupid, and the market disagrees with me, but I see a lot of positives in the quarter report. I grabbed a few shares in the after hours selloff. The conference call will tell the real story.

1 · Reply

JohnTill May. 6 at 7:50 PM

$ALVO Talk about your technical nailbiter. One penny above the 50 MA and giant falling wedge going into important earnings and the FDA finishing today. WOW. Bring on the gap fill!

0 · Reply

ppl_first May. 6 at 2:10 PM

$ALVO Small presence. 297 watchers. This is a revenue producer of biosimilars, just a slow mover, probably never explosive. Won't die, but won't moon either.

1 · Reply

Kosmokrat May. 5 at 7:00 PM

$ALVO What are your assumptions about $ALVO's EPS this year? I was hoping for a bit more than the $0.01 that Yahoo Finance lists, or the $0.03 that are listed here in Stocktwits. Anyway, I think the most important trigger will be the FDA approvals that are currently blocked. Once this is resolved, we should see a nice rebound from these low levels.

1 · Reply

Toffik72 May. 4 at 8:34 AM

$ALVO "Alvotech Looks To Make Good On Two-Year Bet" while we are waiting for th Q1 results and hopefully some good news about FDA inspection, here an interview with Robert Wessmann from 13th of April. Interesting Wessmans claim, that Alvotech is ~2 years ahead by skipping Phase III trials... If proven, it would be faster, cheaper and have scalable advantage front of the competition. Thoughs? https://insights.citeline.com/generics-bulletin/leadership/interviews/alvotech-looks-to-make-good-on-two-year-bet-56WY2TIECJECBBN6DYAM4B563Q/

0 · Reply

JohnTill May. 1 at 3:43 PM

$ALVO I hate to jinx things but in my books this chart is an absolute thing of beauty for a potential breakout to the upside. I am already WAY overweight this name but could not help adding even more 3.30s again. Bring on some positive FDA news and lets get that gap filled!

0 · Reply

Market Cap	1.08B
Revenue (ttm)	586.32M
Net Income (ttm)	27.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	291.25
Profit Margin	4.76%
Debt to Equity Ratio	-4.57

Volume	377,300
Avg Vol	509,194
Day's Range	N/A - N/A
Shares Out	301.81M
Stochastic %K	67%
Beta	0.21
Analysts	Sell
Price Target	$6.60